Moberg Pharma: Transformative Europe-wide partnership with Karo Healthcare accelerates MOB-015/Terclara rollout - Redeye

Redeye comments on the announcement that Moberg Pharma has signed an exclusive license agreement with Karo Healthcare for the commercialisation of MOB-015/Terclara in 19 European markets. The partnership enables a coordinated pan-European launch under the globally recognised Lamisil brand, substantially expanding Moberg’s market reach. We find both the partner choice and agreement structure very encouraging, as it should fast-track a broad and efficient European rollout.

Länk till analysen i sin helhet: https://www.redeye.se/research/1135898/moberg-pharma-transformative-europe-wide-partnership-with-karo-healthcare-accelerates-mob-015-terclara-rollout?utm_source=finwire&utm_medium=RSS